Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Piotroski F-Score 2/9 — signs of financial weakness
- ROE of 676.3% — good return on equity
- Revenue growing at 40% annually
VOLITIONRX LIMITED (VNRX) is a Healthcare company operating in In Vitro & In Vivo Diagnostic Substances, listed on the AMEX , with a market capitalisation of $30 million . Key value metrics: Piotroski F-Score 2 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
VOLITIONRX LIMITED — Fundamental Analysis Summary
On financial health, VNRX shows a weak Piotroski F-Score of 2/9, a signal of deteriorating financial health, and strong return on equity of 676.3% (sector average: -19.8%), and minimal leverage with a debt-to-equity ratio of 0.21.
StockPik's composite Value Score for VNRX is 30/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VNRX shows revenue growing at 40% year-over-year, with earnings growing at 14%.